戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (1語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1  plasmid containing rhodopsin promoter (pRHO-ABCA4).
2 st for mutations in known arRP genes and not ABCA4.
3 and other cytoplasmic and lumenal domains of ABCA4.
4 onger evidence for association with MAFB and ABCA4.
5  clearance is achieved by all-trans-RDHs and Abca4.
6 osomal recessive inheritance of mutations in ABCA4.
7 valence rates per families) were as follows: ABCA4 (20.8%), USH2A (9.1%), RPGR (5.1%), PRPH2 (4.6%),
8                                 Mutations in ABCA4, a member of the ATP-binding cassette (ABC) family
9  disease caused by mutations in the gene for ABCA4, a transporter in photoreceptor outer segments (OS
10 , 488 nm excitation) were acquired in albino Abca4(-/-), Abca4(+/-), and Abca4(+/+) mice (ages 2-12 m
11 r-specific ATP-binding cassette transporter (ABCA4) accelerate the dark adaptation of cones, first, d
12 tated in the present cohort were CACNA1F and ABCA4, accounting for 14.9% (n = 10) and 11.9% (n = 8) o
13  that this variant results in the absence of ABCA4 activity.
14                             Rdh8, Rdh12, and Abca4 all protect the retina and reduce A2E production b
15 owever, the frequency of possibly pathogenic ABCA4 alleles in arRP families was only slightly higher
16        An increasing understanding of causal ABCA4 alleles in arSTGD and arCRD facilitates disease di
17 dodominant inheritance and the presence of 3 ABCA4 alleles within the family.
18 ->C was found to span approximately 96 kb of ABCA4 and did not contain other rare sequence variants.
19 ne therapy in Abca4(-/-) mice using ECO/pRHO-ABCA4 and ECO/pRHO-ABCA4-SV40 nanoparticles induced 36%
20 g for mutations in candidate genes including ABCA4 and PRPH2, DNA from 3 members of the family, inclu
21       The results suggest a possible role of ABCA4 and, in particular, the NBD1 domain in 11-cis-reti
22 itation) were acquired in albino Abca4(-/-), Abca4(+/-), and Abca4(+/+) mice (ages 2-12 months) with
23 nth-old mice with and without Atg7 from both Abca4(-/-) and Abca4(+/+) backgrounds.
24                        RNA sequencing of WT, Abca4(-/-) and Abca4(PV/PV) mice revealed mild gene expr
25                                              Abca4(-/-) and Rdh8(-/-)/Abca4(-/-) mice that are models
26                                     Rdh8(-/-)Abca4(-/-) and Rdh8(-/-)Rdh12(-/-)Abca4(-/-) mice displa
27 d increases, and the fold difference between Abca4(-/-) and wild-type mice was more pronounced (appro
28 (I-C) induced retinal cell death in Rdh8(-/-)Abca4(-/-) and WT mice both in vivo and ex vivo, this wa
29  of both ATP-binding cassette transporter 4 (Abca4) and retinol dehydrogenase 8 (Rdh8) activities.
30  lacking ATP-binding cassette transporter 4 (ABCA4) and retinol dehydrogenase 8 (RDH8), proteins crit
31 identified pathogenic variants in the PRPH2, ABCA4, and CTNNA1 genes, which allowed reclassification
32 cumulation of lipofuscin bisretinoids in the Abca4(-/-) animal model.
33 tions in the photoreceptor-specific flippase ABCA4 are associated with Stargardt disease and many oth
34                            ABCA1, ABCA7, and ABCA4 are members of the ABCA subfamily of ATP-binding c
35                                 Mutations in ABCA4 are responsible for Stargardt disease, a degenerat
36 1 and NOG1 and between CLP and fetal SNPs at ABCA4-ARHGAP29, THADA, FOXE1, and SPRY2.
37 similar for isolated CLO and CLP, except for ABCA4-ARHGAP29.
38                                 Although the ABCA4 array remains a good first-pass screening option,
39 ether all-trans retinol formation depends on Abca4, arrestin, rhodopsin kinase, and the palmitylation
40  rods derived from 129/sv wild-type mice and Abca4-, arrestin-, and rhodopsin kinase-deficient mice a
41 he secondary structure of the ECD2 domain of ABCA4, as well as in its interaction with all-trans-reti
42 role of the ATP-binding cassette transporter ABCA4 associated with Stargardt macular degeneration and
43     The qAF method can differentiate between ABCA4-associated and non-ABCA4-associated BEM and may gu
44 rkers that can aid in the differentiation of ABCA4-associated and non-ABCA4-associated disease.
45 fferentiate between ABCA4-associated and non-ABCA4-associated BEM and may guide clinical diagnosis an
46          Our study, conducted in the largest ABCA4-associated disease cohort reported to date, update
47   Gene replacement is a logical strategy for ABCA4-associated disease, particularly given the current
48  differentiation of ABCA4-associated and non-ABCA4-associated disease.
49                                      Because ABCA4-associated diseases are evolving retinal dystrophi
50 gardt disease, cone-rod dystrophy, and other ABCA4-associated phenotypes were prescreened for mutatio
51 ion in homozygosity in a patient cohort with ABCA4-associated phenotypes.
52                       Patients (n = 38) with ABCA4-associated retinal degeneration (RD) or with retin
53 dt lies at the severe end of the spectrum of ABCA4-associated retinal phenotypes.
54 hort of patients with molecularly-confirmed, ABCA4-associated Stargardt disease (STGD1) relative to n
55 trans-retinal, namely photoreceptor-specific ABCA4 (ATP-binding cassette transporter 4) and RDH8 (ret
56       Human RPE/choroid, eyes harvested from Abca4 (ATP-binding cassette transporter 4) null mutant m
57 ore abundant in mice with a null mutation in Abca4 (ATP-binding cassette transporter 4), the gene cau
58 th and without Atg7 from both Abca4(-/-) and Abca4(+/+) backgrounds.
59 n of an RPE-specific protein was observed in Abca4(-/-) but not in wild-type mice under the same cond
60 uch as rhodopsin, Peripherin-rds, Rom-1, and Abca4, but significantly disrupts the localization of th
61 el, including a putative founder mutation in ABCA4 (c.3260A>G, p.Glu1087Gly), detected in two familie
62 n and was driven by three common variants in ABCA4 (c.5682G > C, c.5814A > G, c.5844A > G), all confe
63  strains and disease models (129S2, C57Bl/6, Abca4(-/-), C3H-Pde6b(rd1/rd1), Rho(-/-), and BALB/c mic
64                            Here we show that ABCA4 can transport N-11-cis-retinylidene-phosphatidylet
65               However, the large size of the ABCA4 cDNA (6.8 kbp) has hampered progress in the develo
66                                          The ABCA4, CNGB3, KCNV2, PDE6C, and RPGR genes were analyzed
67 es that cause inherited macular dystrophies (ABCA4, CTNNA1, and PRPH2).
68 n of toxic bisretinoid compounds as found in ABCA4-deficient mice and individuals with Stargardt macu
69              We report that young adult RDH8/ABCA4-deficient mice have normal M-cone morphology but r
70  technology to subretinally deliver ABCA4 to Abca4-deficient mice.
71 by the RPE due to its slow release from RDH8/ABCA4-deficient rods.
72 ilitate the discovery of factors that modify ABCA4 disease and will also aid in the optimal selection
73              Patients were enrolled from the ABCA4 disease database at Columbia University or by inqu
74 ent with the range of phenotypes observed in ABCA4 disease.
75 etically engineered to lack Rdh8, Rdh12, and Abca4, either singly or in various combinations, were in
76 use models to date are based on knockouts of Abca4, even though the disease is often caused by missen
77 erformed with minigene constructs containing ABCA4 exon 39.
78 equenced in 114 STGD patients with one known ABCA4 exonic mutation revealing, on average, 200 introni
79 flammatory changes were observed in Rdh8(-/-)Abca4(-/-) eyes by RNA expression analysis.
80                             Mutations in the ABCA4 gene and early onset of disease were independent p
81 ne harboring disease-causing variants in the ABCA4 gene and with specified ocular lesions were enroll
82                             Mutations in the ABCA4 gene are a common cause of autosomal recessive ret
83            Loss-of-function mutations in the ABCA4 gene are responsible for a subset of recessive ret
84 any mutations in the coding sequences of the ABCA4 gene are still unknown, and many possibly reside i
85                                The causative ABCA4 gene encodes a protein localizing to photoreceptor
86  c.5461-10T-->C and sequence analysis of the ABCA4 gene for a homozygous proband.
87     STGD patients with genetically confirmed ABCA4 gene mutations seen at the Wilmer Eye Institute wi
88                                   The entire ABCA4 gene open reading frame, including all exons and f
89                                          The ABCA4 gene was analyzed by deep sequencing technology us
90                              Analysis of the ABCA4 gene was performed using microarray analysis, sequ
91                                          The ABCA4 gene was screened for mutations.
92      In the fraction of the cohort where the ABCA4 gene was sequenced completely, the detection rates
93             After complete sequencing of the ABCA4 gene with negative results, the screening for dise
94 ficant association of common variants in the ABCA4 gene with retinal disease, assessed by a score-bas
95 atients (carrying at least 1 mutation in the ABCA4 gene) were followed over 12 months using microperi
96  pathogenicity of the G1961E mutation in the ABCA4 gene, and present the range of retinal phenotypes
97  donor's DNA identified two mutations in the ABCA4 gene, IVS14+1G > C and Phe1440del1 cT, each on a s
98 1, MIM 248200) is caused by mutations in the ABCA4 gene.
99 ossible large deletions or insertions in the ABCA4 gene.
100 uman donor with ARRP due to mutations in the ABCA4 gene.
101 gous or homozygous, variants detected in the ABCA4 gene.
102 re coding region and the splice sites of the ABCA4 gene.
103  least one disease-associated variant of the ABCA4 gene.
104 ople and results from genetic defects in the ABCA4 gene.
105 gnosis and proven pathogenic variants in the ABCA4 gene.
106               STGD is caused by mutations in ABCA4 gene.
107 netic variants in the coding sequence of the ABCA4 gene.
108 (ATP)-binding cassette subfamily A member 4 (ABCA4) gene and who met the following criteria were enro
109    The coding sequences of the RDS, RHO, and ABCA4 genes were screened for disease-causing mutations.
110  ameliorate clinical symptoms resulting from ABCA4 genetic defects.
111                            The entire 140 kb ABCA4 genomic locus was sequenced in 114 STGD patients w
112 stive CAC loci (chr9p21, COL4A1, ATP2B1, and ABCA4) had significant associations with MI, consistent
113  with a recent report on the in vivo role of ABCA4 in 11-cis-retinal transport.
114 e mechanisms: direct involvement of RDH8 and ABCA4 in cone chromophore processing, and an indirect ef
115 ate the pathogenicity of specific alleles of ABCA4 in patients with retinal phenotypes ranging from S
116                       Complete sequencing of ABCA4 in STGD patients identifies compound heterozygous
117 specific ATP-binding cassette transporter 4 (ABCA4), in dark adaptation of mammalian cones.
118 purified and reconstituted ABCA1, ABCA7, and ABCA4 into liposomes for fluorescent-lipid transport stu
119 ific ATP-binding cassette (ABC) transporter, ABCA4, is essential for transport of all-trans-retinal f
120 t significantly lowered RBP4 serum levels in Abca4(-/-) knockout mice with concomitant normalization
121              The sequence variability in the ABCA4 locus is extensive and the non-coding sequences do
122   Defining disease-associated alleles in the ABCA4 locus requires exceptionally well characterized la
123 ggesting that it is a very rare event in the ABCA4 locus.
124  possibly reside in noncoding regions of the ABCA4 locus.
125                    The physiological role of Abca4 may include the translocation of 11-cis-retinal co
126 quired in albino Abca4(-/-), Abca4(+/-), and Abca4(+/+) mice (ages 2-12 months) with a confocal scann
127 ely 2-fold higher in Abca4(-/-) mice than in Abca4(+/+) mice and approximately 20% higher in heterozy
128 vely and qualitatively analyzed in pigmented Abca4(-/-) mice and wild type (WT) controls in vivo.
129 (-/-) Abca4(-/-) mice compared with Rdh8(-/-)Abca4(-/-) mice at 3 and 6 months of age, indicating tha
130 ncreased 10- to 12-fold in 6- to 9-month-old Abca4(-/-) mice compared with controls, while 488 nm AF
131 ted in light-illuminated retinas of Rdh8(-/-)Abca4(-/-) mice compared with nonilluminated retinas.
132 l cells were exhibited by Tlr3(-/-)Rdh8(-/-) Abca4(-/-) mice compared with Rdh8(-/-)Abca4(-/-) mice a
133             The decline in A2E levels in the Abca4(-/-) mice corresponded to reduced photoreceptor ce
134 eveloped CORD, 6-month-old Tlr3(-/-)Rdh8(-/-)Abca4(-/-) mice did not evidence an abnormal retinal phe
135   Rdh8(-/-)Abca4(-/-) and Rdh8(-/-)Rdh12(-/-)Abca4(-/-) mice displayed slowly progressive, severe ret
136  Sirolimus treatment of 6-month-old Rdh8(-/-)Abca4(-/-) mice for 4 months prevented choroidal neovasc
137 s-retinal dimer-PE) also decreases in albino Abca4(-/-) mice reared in cyclic light compared with dar
138                                    In albino Abca4(-/-) mice receiving a diet supplemented with the a
139                                          Old Abca4(-/-) mice revealed a flecked fundus AF pattern at
140 ng of cryostat-sectioned eyes harvested from Abca4(-/-) mice revealed that carbonyl adduct deposition
141       qAF was approximately 2-fold higher in Abca4(-/-) mice than in Abca4(+/+) mice and approximatel
142                     Abca4(-/-) and Rdh8(-/-)/Abca4(-/-) mice that are models of accelerated bisretino
143                  Unlike 3-month-old Rdh8(-/-)Abca4(-/-) mice that developed CORD, 6-month-old Tlr3(-/
144                   Subretinal gene therapy in Abca4(-/-) mice using ECO/pRHO-ABCA4 and ECO/pRHO-ABCA4-
145 ed retinal degeneration in Tlr3(-/-)Rdh8(-/-)Abca4(-/-) mice was milder than that in Rdh8(-/-)Abca4(-
146 h age in mouse eyes and was more abundant in Abca4(-/-) mice, a model of recessive Stargardt disease.
147 ficacy of potential therapeutics in Rdh8(-/-)Abca4(-/-) mice, a rodent model of human age-related mac
148                                   Similar to Abca4(-/-) mice, Abca4(PV/PV) mice showed substantial A2
149 4(-/-) mice was milder than that in Rdh8(-/-)Abca4(-/-) mice, and a 2-fold increased TLR3 expression
150 ounced lipofuscin accumulation in the RPE of Abca4(-/-) mice, ERG and histology showed a slow age-rel
151                  In contrast to RPE cells in abca4(-/-) mice, human RPE cells exposed to abca4(-/-) r
152 induced mitochondrial injury in vitro and in Abca4(-/-) mice, indicating that they could be effective
153 TGD1-like patient and blue light-illuminated Abca4(-/-) mice, lipofuscin and melanolipofuscin granule
154                                           In Abca4(-/-) mice, lipofuscin-related 488 nm AF increased
155                                           In Abca4(-/-) mice, the acute blue light diminished the mea
156 t metabolizes MG and GO were up-regulated in Abca4(-/-) mice.
157 scin bisretinoid formation in the retinas of Abca4(-/-) mice.
158  normal visual cycle, and high in BALB/c and Abca4(-/-) mice.
159 enuated degenerative retinopathy in Rdh8(-/-)Abca4(-/-) mice.
160 was detected by SD-OCT in Rdh8(-/-)Rdh12(-/-)Abca4(-/-) mice.
161 A2E amounts were found in Rdh8(-/-)Rdh12(-/-)Abca4(-/-) mice.
162 -CRRY) into the subretinal space of 4-wk-old Abca4(-/-) mice.
163  prescreened for mutations in ABCA4 with the ABCA4 microarray, resulting in finding 1 of 2 expected m
164 s suggests the existence of at least two non-ABCA4 modifying factors.
165  95% CI 0.635-0.778, P = 1.44 x 10(-11); and ABCA4, most significant SNP rs560426, with OR = 1.432, 9
166                                    Using the abca4(-/-) mouse model for recessive Stargardt, we inves
167 r NTPDase1 was raised in RPE tissue from the ABCA4(-/-) mouse model of Stargardt's retinal degenerati
168        This blue light-illuminated pigmented Abca4(-/-) mouse model presented retinal pigment epithel
169                                The pigmented Abca4(-/-) mouse strain only reflects the early stage of
170 ty of all-trans-retinal, for instance in the Abca4(-/-) mouse, are discussed.
171  described murine model of AMD, the Rdh8(-/-)Abca4(-/-) mouse.
172  as VX-809, can rescue the processing of the ABCA4 mutants, particularly their expression at the cell
173  field data, and 92 patients with identified ABCA4 mutations (46 with 1 mutation, and 47 with 2 or mo
174 age, 21.9+/-8.3 years) than patients without ABCA4 mutations (mean age, 42.1+/-14.9 years).
175 eptors are more severely affected than rods; ABCA4 mutations are the most common cause of this hetero
176                                              ABCA4 mutations as well as age of onset <20 years were s
177 refining our understanding of how individual ABCA4 mutations contribute to phenotype.
178 netic screening of 44 patients revealed >/=2 ABCA4 mutations in 37 patients and single heterozygous m
179  we detected 70.5% and 36.6% of all expected ABCA4 mutations in arSTGD and arCRD patient cohorts, res
180                The pathologic steps by which ABCA4 mutations lead to clinically detectable retinal pi
181                              We suggest that ABCA4 mutations may be associated with a retinitis pigme
182 mentation should be avoided in patients with ABCA4 mutations or other retinal or macular dystrophies
183               All patients were screened for ABCA4 mutations using the ABCR600 microarray, next-gener
184                                  Although no ABCA4 mutations were detected in either patient, whole-e
185                                              ABCA4 mutations were found in 8 of 90 (9%) of AR-CD, and
186                                              ABCA4 mutations were identified in 22 patients, who tend
187 with the CRD phenotype often associated with ABCA4 mutations.
188 as inherited retinal dystrophy, is caused by ABCA4 mutations.
189 he spectrum of retinal dystrophies caused by ABCA4 mutations.
190  finding (n = 105 [45%]) and associated with ABCA4 (n = 73 [70%]), PRPH2 (n = 9 [9%]), CERKL (n = 3 [
191                           Conversely, in the ABCA4-negative group, 22 of 26 eyes (13 of 15 patients)
192 o the subretinal space of 4-5-day-old albino Abca4 null mutant and Abca4 wild-type mice.
193 eline, harboring disease-causing variants in ABCA4 (OMIM 601691), enrolled in the study from 9 center
194 ment activation following exposure to either Abca4(-/-) or wild-type OS.
195 ck complex deposition following ingestion of Abca4(-/-) OS.
196 following exposure to bisretinoid-containing Abca4(-/-) OS.
197 t pathogenic variants were identified in 506 ABCA4 patients, 50 of which were novel.
198 -sensitive amino lipid ECO and a therapeutic ABCA4 plasmid containing rhodopsin promoter (pRHO-ABCA4)
199               In this study, we modified the ABCA4 plasmid with simian virus 40 enhancer (SV40, pRHO-
200                                       In the ABCA4-positive group, 37 of 41 eyes (19 of 22 patients)
201 According to our observations, patients with ABCA4 presenting with 2 truncating variants may first pr
202 aled that it leads to mRNA exon skipping and ABCA4 protein truncation.
203 , surprisingly, only trace amounts of mutant ABCA4 protein were noted in the retina.
204 a-specific ATP binding cassette transporter, ABCA4 protein, is associated with a broad range of inher
205 hosphate (ATP)-binding cassette transporter (ABCA4) protein that is mutated in Stargardt disease (STG
206                                       Mutant ABCA4 proteins expressed heterologously in mammalian cel
207                  For various genes including ABCA4, PRPH2, CDHR1, and PROM1, higher qAF(8) measures w
208                                 We generated Abca4(PV/PV) knock-in mice homozygous for the complex PV
209         RNA sequencing of WT, Abca4(-/-) and Abca4(PV/PV) mice revealed mild gene expression alterati
210                  Similar to Abca4(-/-) mice, Abca4(PV/PV) mice showed substantial A2E and lipofuscin
211 ease-causing mutations in the NBD1 region of ABCA4, R1108C, and R1129C, which occur within regions of
212                          Macular function in ABCA4-RD patients transitioned from lower sensitivity at
213 ht-induced retinal degeneration mouse model (Abca4 (-/-) Rdh8 (-/-)), raloxifene (a benzothiophene-ty
214 re significantly increased in the retinas of Abca4(-/-)Rdh8(-/-) mice after light exposure, suggestin
215 le of CCL3 in retinal degeneration, Ccl3(-/-)Abca4(-/-)Rdh8(-/-) mice and Ccl3(-/-)Mertk(-/-) mice we
216 r retinal inflammation and degeneration than Abca4(-/-)Rdh8(-/-) mice did in age-related chronic reti
217                                     Tlr4(-/-)Abca4(-/-)Rdh8(-/-) mice displayed milder retinal degene
218   Following intense light exposure, Ccl3(-/-)Abca4(-/-)Rdh8(-/-) mice displayed persistent retinal in
219                        In contrast, Ccl3(-/-)Abca4(-/-)Rdh8(-/-) mice exhibited a milder retinal infl
220                                              Abca4(-/-)Rdh8(-/-) mice featuring defective atRAL clear
221 Here we report that bright light exposure of Abca4(-/-)Rdh8(-/-) mice increased atRAL levels in the r
222                      Analysis of the eyes of Abca4(-/-)Rdh8(-/-) mice that display light-induced reti
223                 Exposure of Cx3Cr1(gfp/Delta)Abca4(-/-)Rdh8(-/-) mice to intense light resulted in th
224                                              Abca4(-/-)Rdh8(-/-) mice, which mimic many features of h
225 response to light illumination in retinas of Abca4(-/-)Rdh8(-/-) mice, which showed delayed clearance
226  and increased Ccl4 expression compared with Abca4(-/-)Rdh8(-/-) mice.
227 f Ccl3 (MIP-1a) 24 h after light exposure in Abca4(-/-)Rdh8(-/-) mice.
228  milder retinal degenerative phenotypes than Abca4(-/-)Rdh8(-/-) mice.
229  light-induced photoreceptor degeneration of Abca4(-/-)Rdh8(-/-) mice.
230 er levels of prostaglandin G2 in the eyes of Abca4(-/-)Rdh8(-/-) mice.
231 y, we examined the role of chemokines in the Abca4(-/-)Rdh8(-/-) mouse model of Stargardt disease and
232 3)R) receptors and found they both protected Abca4(-/-)Rdh8(-/-) mouse retinas from light-induced deg
233 tinoid-derived fluorescence and expansion of Abca4(-/-)Rdh8(-/-) mouse rod cell outer segments accomp
234 E cell cultures and of eyecups obtained from Abca4-Rdh8 double knock-out (DKO) mice, respectively.
235 ATP-binding cassette, subfamily A, member 4 (ABCA4)-related retinopathy, is a genetic condition chara
236 sed and drug therapies that aim to alleviate ABCA4-related retinal disease.
237                  A total of 77 patients with ABCA4-related retinopathy and 110 control subjects under
238                Homozygous G1961E mutation in ABCA4 results in a range of retinal pathology.
239 y prevented atrophic changes in the Rdh8(-/-)Abca4(-/-) retina with retinylamine demonstrating the gr
240 ls with rod outer segments from wild-type or abca4(-/-) retinas.
241 12, and the ATP-binding cassette transporter Abca4, retinoid cycle enzymes involved in all-trans-reti
242 l disease and clinical features atypical for ABCA4 retinopathy.
243 here may be more than 1 disease mechanism in ABCA4 retinopathy.
244 pectrum of clinical features consistent with ABCA4 retinopathy.
245                    Neither the activities of Abca4, rhodopsin kinase, and arrestin, nor the palmityla
246                                       Mutant ABCA4 RNA levels approximated WT ABCA4 RNA levels but, s
247      Mutant ABCA4 RNA levels approximated WT ABCA4 RNA levels but, surprisingly, only trace amounts o
248  abca4(-/-) mice, human RPE cells exposed to abca4(-/-) rod outer segments adaptively increased expre
249  levels of complement-activation products in abca4(-/-) RPE cells.
250 ximal beta-HB production was observed in the Abca4(-/-) RPE, in which loss of the ATP-binding cassett
251 ified nine pathogenic variants in six genes (ABCA4, RPE65, MERTK, USH2A, SPATA7, TULP1) in 10 consang
252                                              ABCA4 sequence changes were identified in 85 patients fr
253                                        Three ABCA4 sequence variations identified exclusively in Afri
254                                        Three ABCA4 sequence variations were identified exclusively in
255 atients, 10 unrelated patients shared 1 of 3 ABCA4 sequence variations: c.3602T>G (p.L1201R); c.3899G
256  minor alleles of common genetic variants in ABCA4 significantly reduce susceptibility to develop tox
257  autofluorescence (UWF-FAF) in patients with ABCA4 Stargardt disease (STGD) and correlate these data
258  ABCA1 Tangier mutants and the corresponding ABCA4 Stargardt mutants showed significantly reduced pho
259 d to the retinal pigment epithelium (RPE) in Abca4 (-/-) Stargardt model mice compared to their relev
260 sing polarized primary RPE and the pigmented Abca4(-/-) Stargardt disease mouse model, we provide evi
261                           STGD1 patients and Abca4(-/-) (STGD1) mice exhibit buildup of bisretinoid-c
262 nts and 326 eyes with molecularly confirmed (ABCA4) STGD1 underwent testing with the Nidek MP-1 micro
263            Notably, the deletion of RDH8 and ABCA4 suppressed the dark adaptation of M-cones driven b
264 at ECO formed stable nanoparticles with pRHO-ABCA4-SV40 in the presence of sucrose, but not with sorb
265 (-/-) mice using ECO/pRHO-ABCA4 and ECO/pRHO-ABCA4-SV40 nanoparticles induced 36% and 29% reduction i
266 troduction of SV40 enhancer for plasmid pCMV-ABCA4-SV40 with a CMV promoter.
267 id with simian virus 40 enhancer (SV40, pRHO-ABCA4-SV40) for enhanced gene expression.
268  with age and more so in the Stargardt model Abca4(-/-) than in the wild type strains 129/sv and C57B
269              Following mutation screening of ABCA4, the molecular findings were compared with those o
270 ed DNA NP technology to subretinally deliver ABCA4 to Abca4-deficient mice.
271                       We detected persistent ABCA4 transgene expression for up to 8 months after inje
272                                 In contrast, ABCA4 transported phosphatidylethanolamine in the revers
273 ) is caused by mutations in the gene for the ABCA4 transporter in photoreceptor outer segments.
274 disease caused by dysfunction or loss of the ABCA4 transporter in rods and cones.
275                                 The frequent ABCA4 variant c.5461-10T-->C has a subtle effect on spli
276                                          The ABCA4 variant c.5461-10T-->C is located on a founder hap
277               We found a single heterozygous ABCA4 variant in 11 patients (52%), 2 compound heterozyg
278               Analysis of the most prevalent ABCA4 variant in Spain, c.3386G>T; p.(Arg1129Leu), revea
279                   At least 1 disease-causing ABCA4 variant was identified in 47 patients.
280 % of patients (n = 5), a single heterozygous ABCA4 variant was identified; all these participants had
281 e compared with those with at least 1 milder ABCA4 variant.
282 the genotype-phenotype model established for ABCA4 variants and broadens the mutational spectrum of t
283 etween siblings with STGD1 carrying the same ABCA4 variants is a prevalent phenomenon.
284           We characterized 506 patients with ABCA4 variants using conventional genetic tools and next
285 ion of lipofuscin depends on the severity of ABCA4 variants, precedes other structural changes, and m
286  suggested 12 new likely pathogenic intronic ABCA4 variants, some of which were specific to (isolated
287       This phenotype may be caused by 1 or 2 ABCA4 variants.
288 notypes linked to the presence of additional ABCA4 variants.
289 atively high carrier frequency of pathogenic ABCA4 variants.
290 designed to find the missing disease-causing ABCA4 variation by a combination of next-generation sequ
291  products of lipid peroxidation in eyes from abca4(-/-) versus wild-type mice.
292 tack by the complement system, were lower in abca4(-/-) versus wild-type RPE.
293 ar degeneration (AMD) in humans, deletion of Abca4 was introduced into Atg7(flox/flox);VMD2-rtTA-cre+
294                       Molecular screening of ABCA4 was undertaken.
295 cid sequences of the four soluble domains of ABCA4, we demonstrated that the nucleotide binding domai
296 transport and ATPase activities of ABCA1 and ABCA4 were reduced by 25% in the presence of 20% cholest
297                                 Mutations in ABCA4 were the most common cause of disease in this coho
298  of 4-5-day-old albino Abca4 null mutant and Abca4 wild-type mice.
299 d the interactions of the soluble domains of ABCA4 with both 11-cis- and all-trans-retinal.
300 phenotypes were prescreened for mutations in ABCA4 with the ABCA4 microarray, resulting in finding 1

 
Page Top